Clinical Impact of Rapid Identification of Positive Blood Cultures vs. Internal Laboratory Standard

Overview

In this before-after study, different new methods for bacterial species identification from positive blood cultures will be compared towards historic controls. All samples are analyzed within the routine workflow for bacterial species identification and antibiotic resistance profiling. Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls) will be compared to patients from 2018 and 2019 with a new identification method (cases). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or Matrix-assisted Laser-Desorption/Ionization Time-of-Flight (MALDI-TOF MS). The new identification of positive blood cultures methods include (i) either the newly introduced Biofire FilmArray© Blood Culture Identification (BCID) panel or (ii) in a subset of patients whole genome sequencing (WGS) approaches.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 2020

Interventions

  • Diagnostic Test: conventional identification method: biochemical profiling or MALDI-TOF MS
    • Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
  • Diagnostic Test: new identification method: Biofire FilmArray© BCID panel
    • The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
  • Diagnostic Test: new identification method: metagenomic WGS
    • shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)

Arms, Groups and Cohorts

  • conventional identification methods (controls)
    • Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.
  • new identification method (cases)Biofire FilmArray© BCID panel
    • Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
  • new identification method (cases) WGS approaches
    • Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.

Clinical Trial Outcome Measures

Primary Measures

  • Time to optimal antibiotic treatment in hours from positive blood cultures (hours)
    • Time Frame: 24 hours from collection of blood cultures
    • Time from blood draw for blood culture testing to start of optimal antibiotic treatment (hours)

Secondary Measures

  • Time to effective antibiotic treatment in hours from positive blood cultures (hours)
    • Time Frame: 24 hours from collection of blood cultures
    • Time from blood draw for blood culture testing to start of effective antibiotic treatment (hours)
  • all-cause in hospital mortality (number)
    • Time Frame: from admission to hospital until release from hospital (approximately 30 days)
    • all-cause in hospital mortality (number)
  • duration on ICU in days
    • Time Frame: from admission to ICU until release from ICU (approximately 20 days)
    • duration on ICU in days
  • time to Gram staining and resistance profile from positive blood cultures (hours)
    • Time Frame: 24 hours from collection of blood cultures
    • time to Gram staining and resistance profile from positive blood cultures (hours)

Participating in This Clinical Trial

Inclusion Criteria

  • patients with positive blood cultures hospitalized between August 2016 and October 2019
  • documented refusal of the general consent

Exclusion Criteria

  • outpatients
  • patients hospitalized in other hospitals
  • patients with known bacteremia diagnosed in another hospital

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Basel, Switzerland
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Adrian Egli, PD Dr. med, Principal Investigator, Division of Clinical Bacteriology & Mycology; University Hospital Basel
  • Overall Contact(s)
    • Adrian Egli, PD Dr. med, +41 61 556 57 49, Adrian.egli@usb.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.